December 17, 2014 9:50 PM ET

Biotechnology

Company Overview of DUSA Pharmaceuticals Inc.

Company Overview

DUSA Pharmaceuticals, Inc., a vertically integrated dermatology company, develops and markets Levulan photodynamic therapy (PDT) and other products for common skin conditions primarily in the United States, Canada, and Korea. The company’s marketed products include Levulan Kerastick 20% Topical Solution with PDT, as well as the BLU-U brand light source for the treatment of non-hyperkeratotic actinic keratoses of the face or scalp. It also markets the BLU-U without Levulan PDT for the treatment of moderate inflammatory acne vulgaris and general dermatological conditions. The company was founded in 1991 and is headquartered in Wilmington, Massachusetts. As of December 19, 2012, DUSA Pharmaceut...

25 Upton Drive

Wilmington, MA 01887

United States

Founded in 1991

99 Employees

Phone:

978-657-7500

Fax:

978-657-9193

Key Executives for DUSA Pharmaceuticals Inc.

Chief Executive Officer and President
Age: 64
Chief Financial Officer
Age: 44
Vice President of Operations
Age: 59
Chief Medical Officer and Vice President of Scientific Affairs
Age: 67
Compensation as of Fiscal Year 2014.

DUSA Pharmaceuticals Inc. Key Developments

DUSA Pharmaceuticals Inc. Announces Amendment of Certificate of Incorporation

DUSA Pharmaceuticals Inc. entered into an agreement and plan of merger on November 8, 2012 with Sun Pharmaceutical Industries Limited. The Merger became effective on December 20, 2012. In accordance with the provisions of the merger agreement pertaining to the top-up option, on December 20, 2012, the company amended its certificate of incorporation to designate an additional 35,000,000 shares of its capital stock as company common stock, so that as a result of such designation of shares of capital stock the company has 75,000,000 shares of authorized company common stock.

DUSA Pharmaceuticals Inc. Announces Board Changes

DUSA Pharmaceuticals Inc. entered into an Agreement and Plan of Merger on November 8, 2012 with Sun Pharmaceutical Industries Limited, and Caraco Acquisition Corp. Sun Pharma assigned its rights under the Merger Agreement as of November 16, 2012 to Caraco Pharmaceutical Laboratories Ltd. In accordance with the terms of the Merger Agreement and the Certificate of Merger, the directors of Sun Pharma immediately prior to the effective time, which were Messrs. Kal Sundaram and G.P. Singh, became the directors of the DUSA Pharmaceuticals Inc. following the Merger. Accordingly, on December 20, 2012, each of Messrs. Altomari, Bartash, Casdin, Doman, Haft, Hondros, Moliteus and Wurzer resigned from the Board.

DUSA Pharmaceuticals Inc.(NasdaqGM:DUSA) dropped from NASDAQ Composite Index

DUSA Pharmaceuticals Inc. will be removed from NASDAQ Composite Index

Similar Private Companies By Industry

Company Name Region
Layton BioScience United States
Lifeblood Biological Services, LLC United States
Lazarus Therapeutics LLC United States
Anagen Therapeutics, Inc. United States
KCM Biomedical United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DUSA Pharmaceuticals Inc., please visit www.dusapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.